IL293604A - Dendrimer preparations and methods of drug administration - Google Patents

Dendrimer preparations and methods of drug administration

Info

Publication number
IL293604A
IL293604A IL293604A IL29360422A IL293604A IL 293604 A IL293604 A IL 293604A IL 293604 A IL293604 A IL 293604A IL 29360422 A IL29360422 A IL 29360422A IL 293604 A IL293604 A IL 293604A
Authority
IL
Israel
Prior art keywords
composition
dendrimer
tumor
inhibitors
cancer
Prior art date
Application number
IL293604A
Other languages
English (en)
Hebrew (he)
Original Assignee
Ashvattha Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ashvattha Therapeutics Inc filed Critical Ashvattha Therapeutics Inc
Publication of IL293604A publication Critical patent/IL293604A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/595—Polyamides, e.g. nylon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
IL293604A 2019-12-04 2020-12-04 Dendrimer preparations and methods of drug administration IL293604A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962943705P 2019-12-04 2019-12-04
US202063108186P 2020-10-30 2020-10-30
PCT/US2020/063332 WO2021113651A2 (en) 2019-12-04 2020-12-04 Dendrimer compositions and methods for drug delivery

Publications (1)

Publication Number Publication Date
IL293604A true IL293604A (en) 2022-08-01

Family

ID=74104190

Family Applications (1)

Application Number Title Priority Date Filing Date
IL293604A IL293604A (en) 2019-12-04 2020-12-04 Dendrimer preparations and methods of drug administration

Country Status (9)

Country Link
US (3) US20230226199A1 (enExample)
EP (1) EP4069307A2 (enExample)
JP (1) JP2023504286A (enExample)
CN (1) CN115103689A (enExample)
AU (1) AU2020397063A1 (enExample)
CA (1) CA3163886A1 (enExample)
IL (1) IL293604A (enExample)
PH (1) PH12022551368A1 (enExample)
WO (1) WO2021113651A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021113662A2 (en) 2019-12-04 2021-06-10 Ashvattha Therapeutics, Inc. Dendrimer compositions and methods for drug delivery to the eye
JP2023522984A (ja) 2020-04-24 2023-06-01 アシュバッタ セラピューティクス， インコーポレイテッド 重症急性呼吸促迫症候群の処置のためのデンドリマー組成物および方法
PH12023550133A1 (en) * 2020-07-17 2024-06-24 Ashvattha Therapeutics Inc Dendrimer compositions and methods for drug delivery to injured kidney
JP2023549081A (ja) * 2020-10-30 2023-11-22 アシュバッタ セラピューティクス， インコーポレイテッド Ｐｅｔイメージングおよび放射線療法のための放射標識エーテルデンドリマーコンジュゲート
WO2022192135A1 (en) * 2021-03-08 2022-09-15 Transdermal Biotechnology, Inc. Dendrimer-n-actyl-l-cysteine conjugates for treatment or prevention of aging skin or other indications
TW202313118A (zh) * 2021-06-10 2023-04-01 美商阿什瓦塔治療股份有限公司 樹枝狀體結合物及其使用方法
EP4490158A4 (en) * 2022-03-10 2026-01-07 Curators Of The University Of Missouri The NEW PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITOR, COMPOSITIONS CONTAINING IT, METHODS OF MANUFACTURING IT AND METHODS OF TREATING A DISEASE
WO2023183367A1 (en) * 2022-03-22 2023-09-28 Board Of Regents Of The University Of Nebraska Metformin nanoformulations and methods of use thereof
EP4496568A1 (en) * 2022-03-22 2025-01-29 Board of Regents of the University of Nebraska Metformin nanoformulations and methods of use thereof
CN114796492B (zh) * 2022-05-12 2023-01-13 大连理工大学 一种超声驱动纳米声敏疫苗及其制备和应用
CN116196292B (zh) * 2023-02-16 2024-08-16 东华大学 一种靶向肽修饰的聚酰胺-胺树状大分子复合纳米材料及其制备方法
WO2025183982A1 (en) * 2024-02-28 2025-09-04 Washington State University Psma-targeted dendrimer nanoplatform for cancer detection and therapy
WO2025226820A1 (en) * 2024-04-23 2025-10-30 Ashvattha Therapeutics, Inc. Csf1r inhibitor dendrimer conjugates and uses thereof
CN118108799B (zh) * 2024-04-29 2024-07-12 内蒙古工业大学 基于DMXAA的含Se多肽药物及其制备方法和应用
WO2025259214A1 (en) 2024-06-14 2025-12-18 EGE Kimya San. ve Tic. A.S. Use of dendrimer compounds as anti-skinning agents
WO2025259215A1 (en) 2024-06-14 2025-12-18 EGE Kimya San. ve Tic. A.S. Use of dendrimer compounds as complexing ligands for metal activity enhancement
CN118846078A (zh) * 2024-07-02 2024-10-29 中国人民解放军空军军医大学 Ndrg2基因联合分子靶向抑制剂在制备肾细胞癌治疗药物中的应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3856807A (en) 1972-03-13 1974-12-24 Upjohn Co L-({60 s,5s)-{60 -amino-3-chloro-2-isoxazoline-5-acetic acid
US3878047A (en) 1973-02-02 1975-04-15 Upjohn Co Process for production of AT-125
US5087639A (en) 1988-11-02 1992-02-11 The Upjohn Company Preventing CNS toxicity of acivicin when used with four large neutral amino acids
CA2786794C (en) * 2004-03-23 2017-09-12 Complex Biosystems Gmbh Aromatic polymeric cascade prodrug linker reagent
EP2214646B1 (en) 2007-10-05 2021-06-23 Wayne State University Dendrimers for sustained release of compounds
CA2767163A1 (en) 2009-06-15 2010-12-23 Wayne State University Dendrimer based nanodevices for therapeutic and imaging purposes
WO2011123591A1 (en) 2010-03-31 2011-10-06 Wayne State University Injectable dendrimer hydrogel nanoparticles
US9198973B2 (en) * 2013-06-17 2015-12-01 Fundacion Fraunhofer Chile Research PAMAM, spacer molecule and cafestol polymers
EP3137116B1 (en) * 2014-04-30 2020-12-16 The Johns Hopkins University Dendrimer compositions and their use in treatment of diseases of the eye
ES2910550T3 (es) * 2014-05-21 2022-05-12 Icd Therapeutics Gmbh Conjugados terapéuticos con dendrímeros sulfatados para selección de objetivos intracelulares
EP3180031A1 (en) * 2014-08-13 2017-06-21 The Johns Hopkins University Selective dendrimer delivery to brain tumors
WO2016025745A1 (en) 2014-08-13 2016-02-18 The Johns Hopkins University Dendrimer compositions and use in treatment of neurological and cns disorders
MX2017007873A (es) * 2014-12-15 2017-11-06 Univ Johns Hopkins Formulaciones de sunitinib y metodos para uso de las mismas en el tratamiento de trastornos oculares.
KR101918346B1 (ko) * 2015-05-06 2018-11-13 경북대학교 산학협력단 난용성 활성물질의 수용성 덴드리머 복합체
CN108289872B (zh) * 2015-10-29 2021-04-02 约翰霍普金斯大学 树枝状聚合物组合物和其在坏死性小肠结肠炎和其它胃肠道病症治疗中的用途
US20190142953A1 (en) * 2016-05-10 2019-05-16 Massachusetts Institute Of Technology Dendrimer-Drug Conjugates, Hydrogel Compositions, and Methods
TWI773730B (zh) * 2017-02-22 2022-08-11 瑞典商阿斯特捷利康公司 治療性樹枝狀聚合物
US12290571B2 (en) * 2017-10-05 2025-05-06 Sony Group Corporation Programmable dendritic drugs
WO2019094952A1 (en) * 2017-11-10 2019-05-16 The Johns Hopkins University Dendrimer delivery system and methods of use thereof
WO2020132196A1 (en) * 2018-12-21 2020-06-25 Tiba Biotech Llc Nanoparticle compositions for efficient nucleic acid delivery and methods of making and using the same
WO2021113662A2 (en) * 2019-12-04 2021-06-10 Ashvattha Therapeutics, Inc. Dendrimer compositions and methods for drug delivery to the eye

Also Published As

Publication number Publication date
US20210170040A1 (en) 2021-06-10
US20230226199A1 (en) 2023-07-20
PH12022551368A1 (en) 2023-05-08
CN115103689A (zh) 2022-09-23
CA3163886A1 (en) 2021-06-10
JP2023504286A (ja) 2023-02-02
AU2020397063A1 (en) 2022-07-07
US20230372499A1 (en) 2023-11-23
WO2021113651A3 (en) 2021-08-26
EP4069307A2 (en) 2022-10-12
WO2021113651A2 (en) 2021-06-10

Similar Documents

Publication Publication Date Title
US20230372499A1 (en) Dendrimer compositions and methods for drug delivery
JP7719072B2 (ja) 三分岐ｎ－アセチルガラクトサミン修飾ヒドロキシルポリアミドアミンデンドリマーおよびその使用方法
JP7240311B2 (ja) 薬物送達組成物およびその使用
US12485174B2 (en) HDAC6-activated macrophages, compositions, and uses thereof
WO2017106630A1 (en) Polyacetal polymers, conjugates, particles and uses thereof
WO2025247082A1 (en) An antibody-drug conjugate having two or more different functional small molecules for enhanced treatment of refractory diseases.
ES2863369T7 (es) Terapias inmunoablativas
WO2011097384A2 (en) Tumor targeted delivery of immunomodulators by nanoplymers
US20230390406A1 (en) Star Polymer Drug Conjugates
JP2022523103A (ja) 分岐連結体とアマニタトキシンとの共役体
BR112020009363A2 (pt) métodos e composições para tratar câncer por modificação de múltiplos braços do sistema imunológico
US20210169819A1 (en) Microparticles and nanoparticles having negative surface charges
WO2023122599A1 (en) Glycosylated dendrimers for targeted intracellular delivery
US20230136346A1 (en) Non-adult human dosing of anti-cd30 antibody-drug conjugates
JP2023549464A (ja) Ｂ細胞免疫寛容の誘導及びｍＩｇＭ陽性発現Ｂ細胞リンパ腫の標的化における葉酸及び葉酸修飾の使用
US20240325565A1 (en) Combination treatment for solid tumors including a sting agonist and a ccr2 antagonist
HK40081468A (en) Dendrimer compositions and methods for drug delivery
WO2024040169A2 (en) Methods and compositions for treating cancer with cancer-binding adjuvants
HK40081089A (en) Dendrimer compositions and methods for drug delivery to the eye